Health: pharmaceuticals; drug manufacturers from engaging in certain conduct with pharmacies participating with a 340B program; prohibit. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 17757c. TIE BAR WITH: SB 0095'25
The enactment of SB 94 is expected to have a significant impact on state laws regarding drug distribution and pharmaceutical practices. Specifically, it mandates that covered entities involved in the 340B program must submit reports annually to state departments and legislative bodies. This reporting includes various compliance and performance measures, which are intended to ensure adherence to both state and federal regulations, promote transparency, and evaluate the impact of these programs on local communities.
Senate Bill 94 aims to amend the Public Health Code in Michigan by adding provisions related to the federal 340B drug pricing program. The bill prohibits manufacturers, wholesalers, and wholesale distributor-brokers from denying or limiting the acquisition of 340B drugs by entities that participate in the program or their contracted pharmacies. This legislative effort is designed to enhance accessibility to affordable medication for community health organizations that rely on the 340B program for providing services to underserved populations.
The sentiment surrounding SB 94 is generally supportive among healthcare advocates and community organizations that prioritize equitable access to medications. Proponents view this bill as a crucial step in safeguarding the benefits of the 340B program, which serves essential health services for the low-income and uninsured populations. However, there may also be concerns about the administrative burden placed on 340B entities and whether the increased regulatory oversight could discourage participation in the program.
Notable points of contention regarding SB 94 may arise from pharmaceutical industry stakeholders who could perceive the reporting requirements as restrictive or cumbersome. As the bill interlinks with other pending legislation, its effectiveness will depend on the successful passage of related bills that could impact the overall framework of healthcare regulations in Michigan. The discussions may highlight the balance between ensuring access to affordable drugs and the viability of pharmaceutical companies operating within the state.